Anavex Life Sciences Corp. - Revizia istoricului

127.0.0.1: The LinkTitles extension automatically added links to existing pages (https://github.com/bovender/LinkTitles).

2024-11-24T07:06:51Z

The LinkTitles extension automatically added links to existing pages (https://github.com/bovender/LinkTitles).

← Versiunea anterioară		Versiunea de la data 24 noiembrie 2024 10:06
Linia 2:		Linia 2:

	==Descriere companie==		==Descriere companie==
	Anavex Life Sciences Corp. (www.anavex.com) is a clinical-stage biopharmaceutical company. The Company is engaged in the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX 2-73, is being developed for the treatment of Alzheimer’s disease, Parkinson’s disease and other [[CENTRAL\|central]] nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder caused by mutations in the X-linked gene, methyl-CpG-binding protein 2 (MECP2). Its product candidates also include ANAVEX 3-71, ANAVEX 1-41, ANAVEX 1037 and ANAVEX 1066. ANAVEX 3-71 is a central nervous system (CNS) penetrable potential disease modifying treatment for cognitive impairments. ANAVEX 1037 is designed for the treatment of prostate and pancreatic cancer. ANAVEX 1066 is designed for the potential treatment of neuropathic and visceral pain.		Anavex Life Sciences Corp. (www.anavex.com) is a clinical-stage biopharmaceutical company. The Company is engaged in the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX 2-73, is being developed for the treatment of Alzheimer’s disease, Parkinson’s disease and other [[CENTRAL\|central]] nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder caused by mutations in the X-linked gene, methyl-CpG-binding protein 2 (MECP2). Its product candidates also include ANAVEX 3-71, ANAVEX 1-41, ANAVEX 1037 and ANAVEX 1066. ANAVEX 3-71 is a [[CENTRAL\|central]] nervous system (CNS) penetrable potential disease modifying treatment for cognitive impairments. ANAVEX 1037 is designed for the treatment of prostate and pancreatic cancer. ANAVEX 1066 is designed for the potential treatment of neuropathic and visceral pain.

	==Grafic actiuni companie==		==Grafic actiuni companie==

127.0.0.1: The LinkTitles extension automatically added links to existing pages (https://github.com/bovender/LinkTitles).

2024-09-29T10:19:52Z

The LinkTitles extension automatically added links to existing pages (https://github.com/bovender/LinkTitles).

← Versiunea anterioară		Versiunea de la data 29 septembrie 2024 13:19
Linia 2:		Linia 2:

	==Descriere companie==		==Descriere companie==
	Anavex Life Sciences Corp. (www.anavex.com) is a clinical-stage biopharmaceutical company. The Company is engaged in the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX 2-73, is being developed for the treatment of Alzheimer’s disease, Parkinson’s disease and other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder caused by mutations in the X-linked gene, methyl-CpG-binding protein 2 (MECP2). Its product candidates also include ANAVEX 3-71, ANAVEX 1-41, ANAVEX 1037 and ANAVEX 1066. ANAVEX 3-71 is a central nervous system (CNS) penetrable potential disease modifying treatment for cognitive impairments. ANAVEX 1037 is designed for the treatment of prostate and pancreatic cancer. ANAVEX 1066 is designed for the potential treatment of neuropathic and visceral pain.		Anavex Life Sciences Corp. (www.anavex.com) is a clinical-stage biopharmaceutical company. The Company is engaged in the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX 2-73, is being developed for the treatment of Alzheimer’s disease, Parkinson’s disease and other [[CENTRAL\|central]] nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder caused by mutations in the X-linked gene, methyl-CpG-binding protein 2 (MECP2). Its product candidates also include ANAVEX 3-71, ANAVEX 1-41, ANAVEX 1037 and ANAVEX 1066. ANAVEX 3-71 is a central nervous system (CNS) penetrable potential disease modifying treatment for cognitive impairments. ANAVEX 1037 is designed for the treatment of prostate and pancreatic cancer. ANAVEX 1066 is designed for the potential treatment of neuropathic and visceral pain.

	==Grafic actiuni companie==		==Grafic actiuni companie==

Admin: Pagină nouă: Pagina dedicata companiei Anavex Life Sciences Corp. listata cu simbolul US.AVXL ==Descriere companie== Anavex Life Sciences Corp. (www.anavex.com) is a clinical-stage biopharmaceutical company. The Company is engaged in the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX 2-73, is being developed for the treatment of Alzheimer’s disease, Parkinson’s disease and other central nerv...

2024-09-18T13:40:35Z

Pagină nouă: Pagina dedicata companiei Anavex Life Sciences Corp. listata cu simbolul US.AVXL ==Descriere companie== Anavex Life Sciences Corp. (www.anavex.com) is a clinical-stage biopharmaceutical company. The Company is engaged in the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX 2-73, is being developed for the treatment of Alzheimer’s disease, Parkinson’s disease and other central nerv...

Pagină nouă

Pagina dedicata companiei Anavex Life Sciences Corp. listata cu simbolul US.AVXL

==Descriere companie==
Anavex Life Sciences Corp. (www.anavex.com) is a clinical-stage biopharmaceutical company. The Company is engaged in the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX 2-73, is being developed for the treatment of Alzheimer’s disease, Parkinson’s disease and other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder caused by mutations in the X-linked gene, methyl-CpG-binding protein 2 (MECP2). Its product candidates also include ANAVEX 3-71, ANAVEX 1-41, ANAVEX 1037 and ANAVEX 1066. ANAVEX 3-71 is a central nervous system (CNS) penetrable potential disease modifying treatment for cognitive impairments. ANAVEX 1037 is designed for the treatment of prostate and pancreatic cancer. ANAVEX 1066 is designed for the potential treatment of neuropathic and visceral pain.

==Grafic actiuni companie==
<iframe key="tradeville" path="graficSimbol/US.AVXL" />

==Ultimele stiri despre Anavex Life Sciences Corp. (US.AVXL)==
<dynamicpagelist>
category=US.AVXL
count=10
order=descending
addfirstcategorydate=false
</dynamicpagelist>

[[Categorie:US.AVXL]][[Categorie:Stiri despre companii]]